| Literature DB >> 35202133 |
Magdalena Mróz1, Magdalena Gajęcka1, Katarzyna E Przybyłowicz2, Tomasz Sawicki2, Sylwia Lisieska-Żołnierczyk3, Łukasz Zielonka1, Maciej Tadeusz Gajęcki1.
Abstract
The aim of this study was to determine whether low doses of zearalenone (ZEN) influence the carry-over of ZEN and its metabolites to the bone marrow microenvironment and, consequently, haematological parameters. Pre-pubertal gilts (with a body weight of up to 14.5 kg) were exposed to daily ZEN doses of 5 μg/kg BW (group ZEN5, n = 15), 10 μg/kg BW (group ZEN10, n = 15), 15 μg/kg BW (group ZEN15, n = 15), or were administered a placebo (group C, n = 15) throughout the entire experiment. Bone marrow was sampled on three dates (exposure dates 7, 21, and 42-after slaughter) and blood for haematological analyses was sampled on 10 dates. Significant differences in the analysed haematological parameters (WBC White Blood Cells, MONO-Monocytes, NEUT-Neutrophils, LYMPH-Lymphocytes, LUC-Large Unstained Cells, RBC-Red Blood Cells, HGB-Haemoglobin, HCT-Haematocrit, MCH-Mean Corpuscular Volume, MCHC-Mean Corpuscular Haemoglobin Concentrations, PLT-Platelet Count and MPV-Mean Platelet Volume) were observed between groups. The results of the experiment suggest that exposure to low ZEN doses triggered compensatory and adaptive mechanisms, stimulated the local immune system, promoted eryptosis, intensified mycotoxin biotransformation processes in the liver, and produced negative correlations between mycotoxin concentrations and selected haematological parameters.Entities:
Keywords: bone marrow microenvironment; haematology; low dose; pre-pubertal gilts; zearalenone
Mesh:
Substances:
Year: 2022 PMID: 35202133 PMCID: PMC8880195 DOI: 10.3390/toxins14020105
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
The carry-over factor (CF) and mean () concentrations of ZEN and ZELs (ng/g) in the bone marrow microenvironment of pre-pubertal gilts.
| Exposure | Feed | Total ZEN | Group | CF | Group | CF | Group | CF |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| D1 | 0.8 | 80.5/161.9/242.7 | 5.64 ± 3.24 | 7 × 10−5 | 6.35 ± 3.56 | 39 × 10−6 | 8.17 ± 0.45 | 33 × 10−6 |
| D2 | 1.1 | 101.01/196.9/298.2 | 4.69 ± 4.28 | 46 × 10−6 | 7.08 ± 0.10 | 35 × 10−6 | 6.84 ± 0.18 ●● | 22 × 10−6 |
| D3 | 1.6 | 128.3/481.4/716.7 | 7.74 ± 0.26 | 6 × 10−5 | 7.35 ± 0.25 * | 15 × 10−6 | 7.03 ± 0.14 **,●● | 98 × 10−7 |
|
| ||||||||
| D1–D3 | not applicable | 0 | ||||||
Abbreviation: D1, exposure day 7; D2, exposure day 21; D3, exposure day 42. Experimental groups: Group ZEN5, 5 µg ZEN/kg BW; Group ZEN10, 10 µg ZEN/kg BW; Group ZEN15, 15 µg ZEN/kg BW. LOD > values below the limit of detection were expressed as 0. Statistically significant differences were determined at * p ≤ 0.05 and **,●● p ≤ 0.01; *, ** statistical difference between group ZEN5 vs. group ZEN10 and group ZEN15 on exposure date D3; ●● statistical difference in group 3 between exposure date D1 and exposure dates D2 and D3.
Figure 1Selected haematological parameters on the fourth analytical date (, SD) Key: C, control group; Group ZEN5, 5 μg ZEN/kg BW; Group ZEN10, 10 μg ZEN/kg BW; Group ZEN15, 15 μg ZEN/kg BW. Statistically significant differences: * at p ≤ 0.05; ** at p ≤ 0.01.
Figure 2Selected haematological parameters on the tenth analytical date (, SD). Key: C, control group; Group ZEN5, 5 μg ZEN/kg BW; Group ZEN10, 10 μg ZEN/kg BW; Group ZEN15, 15 μg ZEN/kg BW. Statistically significant differences: * at p ≤ 0.05; ** at p ≤ 0.01.
Selected haematological parameters in group ZEN5 on different analytical dates (, SD).
| Blood Collection Dates | WBC 109/L | MONO % | LUC % | MPV fl |
|---|---|---|---|---|
| 1 | 15.52 ± 7.58 | 5.32 ± 1.06 | 0.88 ± 0.63 bb | 7.36 ± 1.61 cc,ff |
| 2 | 18.8 ± 4.84 | 4.94 ± 1.07 | 1.72 ± 0.99 | 8.94 ± 0.99 a |
| 3 | 18.8 ± 2.71 | 6.04 ± 3.69 | 1.42 ± 0.94 | 7.68 ± 0.55 c,f |
| 4 | 12.39 ± 2.1 ee | 4.3 ± 1.02 | 2.62 ± 0.31 | 7.48 ± 0.54 c,ff |
| 5 | 17.23 ± 0.57 | 3.56 ± 0.55 | 1.26 ± 0.38 | 9.44 ± 1.44 |
| 6 | 15.45 ± 1.41 | 6.78 ± 0.91 | 0.84 ± 0.76 bb | 8.14 ± 0.59 |
| 7 | 12.46 ± 1.37 ee | 3.84 ± 0.89 | 1.44 ± 0.73 | 8.44 ± 0.87 |
| 8 | 15.04 ± 10.37 | 6.4 ± 2.59 | 0.8 ± 0.53 b | 8.82 ± 1.42 |
| 9 | 24.55 ± 5.39 | 5.78 ± 1.18 | 0.6 ± 0.35 bb | 8.82 ± 1.35 |
| 10 | 10.44 ± 3 ee | 2.82 ± 0.84 d | 0.72 ± 0.37 bb | 9.66 ± 1.88 |
Key: Group ZEN5, 5 μg ZEN/kg BW; WBC, White Blood Cells; MONO, Monocytes; LUC, Large Unstained Cells; MPV, Mean Platelet Volume. Statistical symbols: a, relative to date 1; b, relative to date 4; c, relative to date 5; d, relative to date 6; e, relative to date 9; f, relative to date 10. Statistically significant differences: a,b,c,d and f at p ≤ 0.05; bb,cc,ee and ff at p ≤ 0.01.
Selected white blood cell markers in group ZEN10 on different analytical dates (, SD).
| Blood Collection Dates | WBC 109/L | NEUT % | LYMPH % | LUC % | RBC 1012/L | HGB g/L | HCT % | MCV fl | MCHC g/dL | HDW g/dL |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 21.86 ± 2.67 d | 37.68 ± 3.89 | 55.7 ± 3.89 | 0.8 ± 0.64 | 6.68 ± 0.54 | 10.79 ± 0.65 | 37.08 ± 2.19 | 55.6 ± 1.81 | 29.1 ± 1.23 | 1.58 ± 0.13 aa,bb |
| 2 | 22.74 ± 3.6 a,d | 43.7 ± 12.26 a | 50.02 ± 12.12 a | 0.86 ± 0.69 | 6.57 ± 0.38 c | 10.22 ± 0.36 b,cc | 34.98 ± 1.27 bb,cc | 53.3 ± 2.52 | 29.12 ± 0.57 a | 1.57 ± 0.04 a,b |
| 3 | 19.55 ± 3.03 | 45.14 ± 5.14 a | 46.94 ± 3.13 aa | 0.98 ± 0.62 | 6.56 ± 0.17 c | 10.18 ± 0.34 b,cc | 35.48 ± 0.74 bb,cc | 54.14 ± 2.49 | 28.7 ± 0.51 | 1.6 ± 0.08 a,bb |
| 4 | 16.89 ± 2.94 | 29.58 ± 7.88 | 63.9 ± 7.68 | 1.28 ± 0.37 | 6.81 ± 0.39 | 10.5 ± 0.36 | 37.82 ± 1.63 | 55.6 ± 1.75 | 27.78 ± 0.8 | 1.54 ± 0.09 a |
| 5 | 22.6 ± 6.49 a,d | 43.34 ± 11.1 | 48.62 ± 10.43 a | 1.86 ± 0.34 c | 6.83 ± 0.46 | 10.28 ± 0.76 b,c | 35.7 ± 2.87 bb,cc | 52.22 ± 1.6 a | 28.72 ± 0.38 | 1.54 ± 0.05 a |
| 6 | 15.36 ± 3.68 | 33.7 ± 6.15 | 57.92 ± 6.89 | 1.22 ± 0.61 | 6.71 ± 0.33 | 10.62 ± 0.97 | 38.06 ± 2.54 | 56.68 ± 1.98 | 27.86 ± 0.86 | 1.55 ± 0.07 a,b |
| 7 | 13.59 ± 2.68 | 27.28 ± 8.23 | 66.96 ± 8.07 | 0.66 ± 0.45 | 6.51 ± 0.42 b,c | 10.34 ± 0.28 c | 37.56 ± 1.11 | 57.86 ± 2.94 | 27.48 ± 0.54 | 1.43 ± 0.06 |
| 8 | 15.43 ± 5.68 | 34.08 ± 5.43 | 58.78 ± 5.47 | 1.64 ± 0.01 | 7.35 ± 0.33 | 11.54 ± 0.6 | 40.54 ± 2.56 | 55.18 ± 3.32 | 28.44 ± 0.6 | 1.44 ± 0.05 |
| 9 | 19.81 ± 3.64 | 39.6 ± 5.69 | 53.58 ± 6.26 | 0.52 ± 0.15 | 7.47 ± 0.41 | 11.7 ± 0.43 | 40.92 ± 0.86 | 54.84 ± 2.3 | 28.54 ± 0.94 | 1.53 ± 0.06 a |
| 10 | 12.85 ± 3.75 | 40.4 ± 6.31 | 53.52 ± 6.83 | 0.88 ± 0.21 | 6.83 ± 0.4 | 10.7 ± 0.55 | 37.34 ± 1.23 | 54.74 ± 2.65 | 28.62 ± 0.79 | 1.54 ± 0.08 a |
Key: Group ZEN10, 10 μg ZEN/kg BW; WBC, White Blood Cells; NEUT, Neutrophils; LYMPH, Lymphocytes; LUC, Large Unstained Cells; RBC, Red Blood Cells; HGB, Haemoglobin; HCT, Haematocrit; MCV, Mean Corpuscular Volume; MCHC, Mean Corpuscular Haemoglobin Concentrations; HDW, Haemoglobin Distribution Width. Statistical symbols: a, relative to date 7; b, relative to date 8; c, relative to date 9; d, relative to date 10. Statistically significant differences: a,b,c and d at p ≤ 0.05; aa,bb and cc at p ≤ 0.01.
Selected haematological parameters in group ZEN15 on different analytical dates (, SD).
| Blood Collection Dates | WBC 109/L | NEUT % | LYMPH % | EOS % | MPV fl |
|---|---|---|---|---|---|
| 1 | 22.01 ± 3.85 ee,ff | 52.92 ± 7.91 | 39.96 ± 8.22 e | 2.4 ± 1.47 | 8.22 ± 1.65 |
| 2 | 19.83 ± 1.35 e,f | 43.7 ± 6.64 | 48.62 ± 5.62 | 1.32 ± 0.52 | 7.68 ± 1.55 a |
| 3 | 20.73 ± 2.21 e,f | 44.92 ± 7.66 | 46.42 ± 6.85 | 1.96 ± 0.65 | 7.50 ± 0.45 |
| 4 | 15.09 ± 14.43 | 38.54 ± 7.92 | 55.38 ± 7.23 | 0.64 ± 0.27 a | 8.51 ± 1.12 |
| 5 | 22.33 ± 5.96 ee,ff | 48.16 ± 12.12 | 45.62 ± 10.12 | 1.22 ± 0.43 | 7.58 ± 1.05 aa,b,c |
| 6 | 16.66 ± 3.96 | 37 ± 5.58 | 54.14 ± 5.95 | 1.6 ± 0.41 | 7.84 ± 1.09 |
| 7 | 10.79 ± 2.53 | 26.44 ± 6.28 a,d | 66.12 ± 4.45 | 0.74 ± 0.23 a | 7.44 ± 1.32 |
| 8 | 19.04 ± 2.47 | 41.32 ± 11.48 | 49.64 ± 11.23 | 1.9 ± 0.76 | 8.38 ± 2.72 |
| 9 | 14.8 ± 10.25 | 29.02 ± 20.07 a | 40.37 ± 27.41 e | 1.15 ± 0.82 | 8.85 ± 2.46 |
| 10 | 10.73 ± 1.78 | 39.68 ± 6.79 | 53.94 ± 7.3 | 1.44 ± 1.05 | 8.28 ± 1.05 aa,b,cc |
Key: Group ZEN15, 15 μg ZEN/kg BW; WBC, White Blood Cells; NEUT, Neutrophils; LYMPH, Lymphocytes; EOS, Eosinophils; MPV, Mean Platelet Volume. Statistical symbols: a, relative to date 1; b, relative to date 3; c, relative to date 4; d, relative to date 5; e, relative to date 7; f, relative to date 10. Statistically significant differences: a,b,c,d,e and f at p ≤ 0.05; aa,cc,ee and ff at p ≤ 0.01.
Platelet count in the experimental groups on different analytical dates (, SD).
| Blood Collection Dates | PLT 109/L Group ZEN5 | PLT 109/L Group ZEN10 | PLT Clumps % Group ZEN10 | PLT 109/L Group ZEN15 | PLT Clumps % Group ZEN15 |
|---|---|---|---|---|---|
| 1 | 405.4 ± 295.39 | 690.2 ± 121.87 e | 26.4 ± 14.75 | 479.8 ± 214.68 | 19.8 ± 18.07 |
| 2 | 522.6 ± 112.81 | 763 ± 107.01 d,ee | 19.8 ± 18.07 | 668 ± 144.82 d,e | 19.8 ± 18.07 |
| 3 | 745 ± 54.41 e | 813.2 ± 149.05 c,dd,ee | 0 ± 0 | 753.8 ± 167.69 a,dd,ee | 0 ± 0 |
| 4 | 741.4 ± 89.6 e | 734.6 ± 131.75 d,e | 26.4 ± 14.75 | 501.6 ± 62.13 b | 33 ± 0 b |
| 5 | 517.2 ± 162.41 | 800.2 ± 212.97 c,dd,ee | 33 ± 0 bb | 718.2 ± 129.56 a,d,ee | 26.4 ± 14.75 |
| 6 | 645.2 ± 140.47 | 650.6 ± 238.35 | 19.8 ± 18.07 | 635.4 ± 38.01 e | 19.8 ± 18.07 |
| 7 | 463.6 ± 83.09 | 569.4 ± 132.14 | 26.4 ± 14.75 | 607.8 ± 203.15 | 13.2 ± 18.07 |
| 8 | 454 ± 317.27 | 617.2 ± 180.88 | 13.2 ± 18.07 | 626.6 ± 263.92 e | 19.8 ± 18.07 |
| 9 | 595.6 ± 172.33 | 497.2 ± 101.9 | 33 ± 0 bb | 394 ± 294.02 | 24.75 ± 16.5 |
| 10 | 369.4 ± 118.85 | 478.2 ± 151.9 | 33 ± 0 bb | 386.6 ± 158.7 | 33 ± 0 b |
Key: PLT count in groups 1, 2, and 3; PLT clumps in groups 2 and 3. Statistical symbols: a, relative to date 1; b, relative to date 3; c, relative to date 7; d, relative to date 9; e, relative to date 10. Statistically significant differences: a,b,c,d and e at p ≤ 0.05; bb,dd and ee at p ≤ 0.01.
Correlation coefficients (Pearson’s r).
| Exposure Date | Experimental Groups | PLT | WBC | RBC |
|---|---|---|---|---|
| D1 | Group ZEN5 | −0.739 | −0.362 | −0.456 |
| Group ZEN10 | 0.685 | −0.502 | −0.189 | |
| Group ZEN15 | −0.590 | −0.336 | −0.869 | |
| D2 | Group ZEN5 | −0.251 | −0.851 | −0.424 |
| Group ZEN10 | −0.559 | −0.325 | −0.832 | |
| Group ZEN15 | −0.682 | −0.797 | −0.565 | |
| D3 | Group ZEN5 | −0.772 | −0.230 | −0.752 |
| Group ZEN10 | −0.731 | −0.451 | −0.300 | |
| Group ZEN15 | −0.436 | −0.128 | −0.738 |
Key: Ratio of ZEN concentrations in the bone marrow microenvironment and blood morphotic components (RBC, WBC, and PLT) on different exposure dates (D1, D2, and D3: exposure days 7, 21, and 42, respectively). The mycotoxin was administered once daily before morning feeding (group ZEN5, 5 μg ZEN/kg BW; group ZEN10, 10 μg ZEN/kg BW; group ZEN15, 15 μg ZEN/kg BW). Samples were collected from pre-pubertal gilts immediately before slaughter.
Figure 3Selected haematological parameters in groups (). Key: C, control group; Group ZEN5, 5 μg ZEN/kg BW; Group ZEN10, 10 μg ZEN/kg BW; Group ZEN15, 15 μg ZEN/kg BW.
Declared composition of the complete diet.
| Parameters | Composition Declared by the Manufacturer (%) |
|---|---|
| Soybean meal | 16 |
| Wheat | 55 |
| Barley | 22 |
| Wheat bran | 4.0 |
| Chalk | 0.3 |
| Zitrosan | 0.2 |
| Vitamin-mineral premix 1 | 2.5 |
1 Composition of the vitamin-mineral premix per kg: vitamin A, 500.000 IU; iron, 5000 mg; vitamin D3, 100.000 IU; zinc, 5000 mg; vitamin E (alpha-tocopherol), 2000 mg; manganese, 3000 mg; vitamin K, 150 mg; copper (CuSO4·5H2O), 500 mg; vitamin B1, 100 mg; cobalt, 20 mg; vitamin B2, 300 mg; iodine, 40 mg; vitamin B6, 150 mg; selenium, 15 mg; vitamin B12, 1500 μg; L-lysine, 9.4 g; niacin, 1200 mg; DL-methionine+cystine, 3.7 g; pantothenic acid, 600 mg; L-threonine, 2.3 g; folic acid, 50 mg; tryptophan, 1.1 g; biotin, 7500 μg; phytase+choline, 10 g; ToyoCerin probiotic+calcium, 250 g; antioxidant+mineral phosphorus and released phosphorus, 60 g; magnesium, 5 g; sodium and calcium, 51 g.